SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Pharmos(PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Richard Huth who wrote (1397)10/13/1998 12:45:00 PM
From: yosi s  Read Replies (1) of 1491
 
I would like to point out that in Phase 2 study in all groups hu211
showed improvement. However it was much more distinct in the more severe group.

Let me explain why I feel it is important.

In the more severe group there is a greater injury thus more chance for hu 211 to show its effectiveness.

In the less afflicted group even doing nothing some people will recover eventually. so it is harder to show that medication is effective, but hu211 sped up recovery. so it is working, they just need a bigger study.
Let me eleborate. If you get the common cold it is disabling but it will resolve no matter the treatment. but a medication is effective it it will help you get over your cold sooner.

Same here in 3 month you could see those that gotten better sooner.

What is important is the study design of phase3 to show significance difference in faster healing in the group that were to get better anyway. and more healing in the severe group.. numbers that are seen in phase 2.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News